ONLINE FIRST
Stuart R. Lessin, MD; Madeleine Duvic, MD; Joan Guitart, MD; et al.
free access
JAMA Dermatol. 2013;149(1):25-32. doi:10.1001/2013.jamadermatol.541
To evaluate the efficacy and safety of a novel gel in the treatment of mycosis fungoides, Lessin and colleagues compared response rates to mechlorethamine, 0.02%, gel vs compounded ointment in 260 patients with stage IA to IIA disease. Tumor response and adverse events were assessed, as well as serum drug levels in a subset of patients.
Joi B. Carter, MD; Matthew M. Johnson, MD; Tiffany L. Chua, MA, MPH; et al.
free access
JAMA Dermatol. 2013;149(1):35-42. doi:10.1001/jamadermatol.2013.746
Carter and coauthors identified factors associated with poor outcomes in perineurally invasive squamous cell carcinoma.
ONLINE FIRST
Sven Schneider, PhD, MA; Katharina Diehl, Dipl-Soz; Christina Bock, Dipl-Inform Med, MSc; et al.
free access
JAMA Dermatol. 2013;149(1):43-49. doi:10.1001/2013.jamadermatol.562
Schneider and colleagues calculate sunbed use prevalence rates, investigate the motivations for tanning, and identify typical target groups for interventions to prevent skin cancer.
ONLINE FIRST
David M. Ozog, MD; Austin Liu, MD; Marsha L. Chaffins, MD; et al.
free access
JAMA Dermatol. 2013;149(1):50-57. doi:10.1001/2013.jamadermatol.668
Ozog et al assessed mature burn scars treated with a fractional carbon dioxide laser for changes in histological architecture, types I and III collagen ratios, density of elastic tissue, and subjective measures of clinical improvements.
Antonia Lloyd-Lavery, BM BCh, MA, MRCP; Ching-Chi Chi, MD, MMS, DPhil; Fenella Wojnarowska, MA, DM, FRCP; et al.
free access
JAMA Dermatol. 2013;149(1):58-62. doi:10.1001/2013.jamadermatol.376
Lloyd-Lavery et al investigate the possible association between bullous pemphigoid and multiple drugs in a retrospective case-control study in the United Kingdom.
Rokea A. el-Azhary, MD, PhD; Allison K. Arthur, MD; Mark D. P. Davis, MD; et al.
free access
JAMA Dermatol. 2013;149(1):63-67. doi:10.1001/2013.jamadermatol.5
el-Azhary and colleagues report their experience with low-dose tissue plasminogen activator in the treatment of calciphylaxis.